Key result
Redo mitral valve replacement significantly improved mitral valve area from 1.28 to 2.9 cm² and reduced transmitral gradient from 15.3 to 2.3 mmHg, with 94% of patients experiencing improved NYHA functional class.
Why the study?
Does redo mitral valve replacement improve clinical and echocardiographic outcomes in patients with symptomatic mitral restenosis after previous commissurotomy?
Observational (n=167)
No
Does redo mitral valve replacement improve clinical and echocardiographic outcomes in patients with symptomatic mitral restenosis after previous commissurotomy?
Absolute Event Rate: 2.9% vs 1.28%
Redo mitral valve replacement provides favorable early clinical and echocardiographic improvements in patients with symptomatic restenosis following prior commissurotomy.
Single-center redo MVR series suggests acceptable early outcomes; leaves open need for multicenter prospective validation.
This study is based on the findings of a single surgeon’s practice of mitral valve replacement of 167 patients from April 2005 to June 2017 who developed symptomatic mitral restenosis after closed or open mitral commisurotomy. Both clinical and color doppler echocardiographic data of peri-operative and six months follow-up period were evaluated and compared to assess the early outcome of the redo mitral valve surgery. With male-female ratio of 1: 2.2 and after a duration of 6 to 22 years symptom free interval between the redo procedures, the selected patients with mitral valve restenosis undergone valve replacement with either mechanical valve in 62% cases and also tissue valve in 38% cases. Particular emphasis was given to separate the adhered pericardium from the heart completely to ameliorate base to apex and global contraction of the heart. Besides favorable post-operative clinical outcome, the echocardiographic findings were also encouraging as there was statistically significant increase in the mitral valve area and ejection fraction with significant decrease in the left atrial diameter, pressure gradient across the mitral valve and pulmonary artery systolic pressure. Therefore, in case of inevitable mitral restenosis after closed or open commisurotomy, mitral valve replacement is a promising treatment modality.
No takes yet. Share an insight, caveat, or question.
Ranjan et al. (2018) conducted an observational in Symptomatic mitral restenosis (n=167). Redo mitral valve replacement vs. Pre-operative baseline was evaluated on Mitral valve area (cm²). Redo mitral valve replacement significantly improved mitral valve area from 1.28 to 2.9 cm² and reduced transmitral gradient from 15.3 to 2.3 mmHg, with 94% of patients experiencing improved NYHA functional class.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: